Inspire Medical Systems, Inc. (NYSE:INSP) Receives Consensus Rating of “Hold” from Analysts

Inspire Medical Systems, Inc. (NYSE:INSP) has received a consensus rating of “Hold” from the nineteen analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $104.2353.

Several research analysts recently commented on the company. Wells Fargo & Company set a $70.00 price objective on Inspire Medical Systems and gave the company an “equal weight” rating in a research note on Thursday, February 12th. UBS Group set a $67.00 target price on shares of Inspire Medical Systems in a research note on Friday, February 13th. Wolfe Research lowered shares of Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a report on Friday, February 13th. Truist Financial reduced their target price on shares of Inspire Medical Systems from $96.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday, February 12th. Finally, Royal Bank Of Canada decreased their price target on shares of Inspire Medical Systems from $90.00 to $68.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 12th.

Inspire Medical Systems Trading Down 2.8%

NYSE:INSP opened at $54.81 on Friday. The stock has a 50 day moving average of $70.65 and a two-hundred day moving average of $85.05. Inspire Medical Systems has a 12 month low of $53.11 and a 12 month high of $172.95. The firm has a market cap of $1.57 billion, a P/E ratio of 11.01, a price-to-earnings-growth ratio of 2.79 and a beta of 0.74.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.96. The business had revenue of $269.08 million for the quarter, compared to the consensus estimate of $264.02 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The business’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.15 earnings per share. On average, research analysts forecast that Inspire Medical Systems will post 2.16 earnings per share for the current year.

Institutional Trading of Inspire Medical Systems

Hedge funds have recently bought and sold shares of the business. Manning & Napier Advisors LLC acquired a new position in shares of Inspire Medical Systems during the 3rd quarter worth approximately $32,000. CWM LLC increased its holdings in shares of Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after purchasing an additional 242 shares during the last quarter. Havemeyer Place LP acquired a new stake in shares of Inspire Medical Systems in the fourth quarter valued at approximately $39,000. V Square Quantitative Management LLC purchased a new position in Inspire Medical Systems during the fourth quarter worth approximately $40,000. Finally, Smartleaf Asset Management LLC lifted its position in Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after buying an additional 205 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.